Company news

Niagen Bioscience, Inc. news in 2023

Niagen Bioscience, Inc.'s news releases, calls and decks from 2023, newest first.

View company

ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®

December 19, 2023

Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+

December 11, 2023

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)

November 29, 2023

Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients

November 14, 2023

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023

November 8, 2023

ChromaDex Corporation Reports Third Quarter 2023 Financial Results

November 7, 2023

ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide

October 31, 2023

ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

October 30, 2023

ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line

October 25, 2023

A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients

October 1, 2023

Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN

August 23, 2023

ChromaDex Corporation Reports Second Quarter 2023 Financial Results

August 8, 2023

ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness

August 7, 2023

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series

August 6, 2023

ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

August 1, 2023

Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects

July 17, 2023

ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP™), the Industry Leading Research Program Advancing the Science of NAD+ and Healthy Aging

June 15, 2023

ChromaDex to Participate in the LD Micro Invitational XIII

May 29, 2023

ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference

May 10, 2023

ChromaDex Corporation Reports First Quarter 2023 Financial Results

May 9, 2023

ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

May 1, 2023

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results

March 7, 2023

ChromaDex to Participate at the 35th Annual ROTH Capital Partners Conference on March 13, 2023

March 5, 2023

ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023

February 26, 2023

ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space

February 21, 2023

A Letter from the ChromaDex Chief Executive Officer

February 20, 2023

ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)

January 11, 2023

ChromaDex Named Brianna Gerber Chief Financial Officer

January 4, 2023

Calls in 2023

Decks in 2023